Lymphodepleting chemotherapy has been the standard pretreatment in all FDA-approved CAR T therapies for leukemia and lymphoma, and successful treatment of autoimmune diseases with CD19-targeting CAR T cells included a lymphodepleting pre-conditioning regimen [43, 45, 47, 48]. This evidence concerns the gene CD19 and lymphoma.